Bausch & Lomb: OptiPranolol (metipranolol ophthalmic solution) 0.3%

OptiPranolol^® is a time-tested option for your patients with open-angle glaucoma or ocular hypertension.

In clinical studies, OptiPranolol exhibited comparable efficacy to timolol maleate 0.5% ophthalmic solution.^1-3 OptiPranolol may also result in less impairment of exercise-induced tachycardia and has less potential for systemic beta blockade.³

	Key Benefits		Contraindications
	Package Insert

Time-tested beta-blocker with over half a million new prescriptions written since 1996²

Effective IOP control

Significantly reduced impact on exercise-induced tachycardia

Color-coded yellow cap minimizes risk of selecting an inappropriate medication

OptiPranolol ophthalmic solution is contraindicated in patients with bronchial asthma or a history of bronchial asthma, or severe chronic pulmonary disease; symptomatic sinus bradycardia; greater than a first degree atrioventricular block; cardiogenic shock; or overt cardiac failure.







					Increase your patient base and your knowledge of the latest surgical tools and techniques. Discover how.





					Build your practice. Create your own Web page. We've even prepared a sample to give you some ideas.


	¹ Retrospective review of IOP control after conversion from Timolol 0.5% to Metipranolol 0.3%. ² BAL 9302 - Data on file at Bausch & Lomb Pharmaceuticals, Inc. ³ Rolando M et al. Glaucoma. 1989;11:27-30.